Compare Amylx Pharmaceuticals Inc (AMLX) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Genuine Parts Company — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Genuine Parts Company trades at $125.62 (market cap $17.29B). The key difference: Genuine Parts Company is far larger — about 8.7× Amylx Pharmaceuticals Inc's market cap, and Genuine Parts Company pays a 3.38% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GPC | |
|---|---|---|
Market Cap | $1.98B | $17.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $149.26 |
52-Week Low | $7.64 | $92.47 |
Enterprise Value | $1.70B | $23.50B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
GPC trades at $125.62, up 1.09% with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $24.3B in 2025, though net margins compressed to 0.24%. Analyst consensus is mixed with 43% buy ratings and a $133 price target. Recent news highlights GPC's 70-year dividend growth streak and upcoming Q2 2026 earnings report on July 21, 2026.
GPC offers income stability with its Dividend King status but faces profitability challenges. The stock trades near analyst targets with moderate upside potential. Key risks include margin pressure from rising costs and competitive threats in auto parts distribution. Institutional sentiment remains cautiously optimistic given the stable dividend history amid earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
